Provided by Tiger Trade Technology Pte. Ltd.

Lexeo Therapeutics

3.62
+0.24007.10%
Post-market: 3.60-0.0200-0.55%16:49 EDT
Volume:2.89M
Turnover:10.27M
Market Cap:297.01M
PE:-3.16
High:3.68
Open:3.38
Low:3.30
Close:3.38
52wk High:10.99
52wk Low:2.98
Shares:82.05M
Float Shares:51.23M
Volume Ratio:1.08
T/O Rate:5.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1457
EPS(LYR):-1.8634
ROE:-46.76%
ROA:-27.59%
PB:1.26
PE(LYR):-1.94

Loading ...

Lexeo Therapeutics to Present New Neurologic Assessment Data on Lx2006 Friedreich Ataxia Gene Therapy at MDS 2026

Reuters
·
Yesterday

Lexeo Therapeutics Announces Oral Presentation of Lx2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (Mds)

THOMSON REUTERS
·
Yesterday

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)

GlobeNewswire
·
Yesterday

Lexeo Therapeutics Reports Unregistered Equity Issuances Post-Merger

TIPRANKS
·
Sep 30

Lexeo Therapeutics Issues USD 3 Million in Unregistered Shares in Mantle Merger

Reuters
·
Sep 30

Lexeo Therapeutics Price Target Maintained with a $15.00/Share by Leerink Partners

Dow Jones
·
Sep 23

Press Release: Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX(TM) for Program Designed to Treat Friedreich Ataxia

Dow Jones
·
Sep 23

Lexeo Therapeutics to Join Stifel Virtual Cardiometabolic Forum Fireside Chat

Reuters
·
Sep 23

Lexeo Therapeutics enter into agreement to acquire Mantle Therapeutics

TIPRANKS
·
Sep 22

Lexeo Therapeutics expands FA pipeline with Mantle acquisition

TIPRANKS
·
Sep 22

Lexeo Therapeutics Agrees to Buy Mantle Therapeutics for up to $21.3 Million

Reuters
·
Sep 22

Lexeo Therapeutics, - Maintains Cash Runway Guidance into 2028

THOMSON REUTERS
·
Sep 22

Lexeo Therapeutics Enters into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

THOMSON REUTERS
·
Sep 22

Lexeo Therapeutics, - Deal Includes up to $13 Mln in Milestone Payments, Total Potential $21.30 Mln

THOMSON REUTERS
·
Sep 22

Lexeo Therapeutics, - to Pay $8.30 Mln Upfront to Mantle Shareholders

THOMSON REUTERS
·
Sep 22

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

GlobeNewswire
·
Sep 22

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September

GlobeNewswire
·
Sep 02

Lexeo Therapeutics Releases Corporate Presentation Outlining Cardiac Gene Therapy Pipeline, AAVrh.10 Platform

Reuters
·
Aug 12

Lexeo Therapeutics Q2 EPS $(0.30) Misses $(0.28) Estimate

Benzinga Earnings
·
Aug 12

Lexeo Net Loss Narrows to $25.9 Million in Q2 FY26; R&D Expenses Rise to $19 Million

Reuters
·
Aug 12